Amy Thompson and Arun Gill[email protected]PACS/VNAOutpatient imaging, teleradiology shape U.S. radiology marketAmy Thompson and Arun Gill of Signify Research delve into the market dynamics driving growth in the utilization of outpatient imaging and teleradiology services in the U.S. market.October 18, 2022Page 1 of 1Top StoriesWomens ImagingCancer incidence on rise in younger people, womenEarly-onset cancer incidence trends are rising among younger people, and women carry more of the burden.AssociationsFinancial shock waves strike close to radiology researchersMRICNN techniques outperform conventional DL for Alzheimer's diagnosisWomens ImagingAbout half of women undecided on AI's use in breast imagingISMRM 2025ISMRM president outlines key highlights of the upcoming annual meeting in Honolulu
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
